Journal of the National Cancer Center (Sep 2022)

The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences

  • Yulin Hu,
  • Caining Zhao,
  • Ren Ji,
  • Wenqi Chen,
  • Qi Shen,
  • CL Chiang,
  • Jeff Chan,
  • Lingyu Ma,
  • Hongwei Yang,
  • Tiffany Wong,
  • Susannah Ellsworth,
  • Chung-Mau Lo,
  • Laura A. Dawson,
  • Feng-Ming (Spring) Kong

Journal volume & issue
Vol. 2, no. 3
pp. 171 – 182

Abstract

Read online

Hepatocellular carcinoma (HCC) is a common malignancy with high mortality rates. While surgery can be curative in early-stage disease, 80% of patients cannot undergo surgical resection. Stereotactic body radiotherapy (SBRT), an emerging, non-invasive, precision treatment, has shown promising results across various stages of HCC and has thus been adopted in practice to varying degrees around the world. This article aims to review current guideline recommendations on SBRT, clinical evidence, and outcome comparisons with other local treatment modalities. Attempts are also made to compare the differences in clinical trials between Asian and Western countries.

Keywords